Personal clinical trial finder
The information presented in the Myeloma Canada Personalized Clinical Trials Search Tool is from the International Clinical Trials database at
ClinicalTrials.gov,
indexed by the U.S. National Library of Medicine. Although the menu is in French, the details of the studies are only available in English.
Your search criteria - 46 result(s)
POSTED : 2008-12-01 |
START DATE : 2008-11-27 |
LAST UPDATE : 2015-07-23
Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2009-05-09 |
LAST UPDATE : 2024-07-09
Collection of Tissue Samples for Cancer Research
Condition:
Multiple MyelomaMyelodysplastic Syndromes
Study phase:
Recruitment status: Recruiting
Study phase:
Recruitment status: Recruiting
Nearest centres:
POSTED : 2012-08-15 |
START DATE : 2012-08-13 |
LAST UPDATE : 2023-04-26
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Nearest centres:
POSTED : 2013-04-24 |
START DATE : 2013-04-19 |
LAST UPDATE : 2023-02-16
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase:
Recruitment status: Recruiting
Study phase:
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2017-09-05 |
LAST UPDATE : 2024-07-22
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1
Recruitment status: Recruiting
Study phase: Phase 1
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2017-09-27 |
LAST UPDATE : 2024-07-17
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Condition:
Multiple MyelomaLymphoma, Non-Hodgkin
Study phase: Phase 2
Recruitment status: Recruiting
Study phase: Phase 2
Recruitment status: Recruiting
Nearest centres:
POSTED : 2018-10-11 |
START DATE : 2018-09-25 |
LAST UPDATE : 2023-12-05
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Condition:
MeningiomaColorectal Neoplasms, Hereditary NonpolyposisUterine NeoplasmsHamartoma Syndrome, MultipleSyndrome
Study phase:
Recruitment status: Recruiting
Study phase:
Recruitment status: Recruiting
Nearest centres:
POSTED : 2019-07-18 |
START DATE : 2019-04-24 |
LAST UPDATE : 2020-03-27
Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients
Condition:
Hematologic Neoplasms
Study phase: N/A
Recruitment status: Recruiting
Study phase: N/A
Recruitment status: Recruiting
Nearest centres:
POSTED : 2019-08-28 |
START DATE : 2019-08-07 |
LAST UPDATE : 2023-08-11
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : 2019-09-16 |
START DATE : 2019-09-13 |
LAST UPDATE : 2024-05-17
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1
Recruitment status: Recruiting
Study phase: Phase 1
Recruitment status: Recruiting
Nearest centres:
POSTED : 2019-10-15 |
START DATE : 2019-10-11 |
LAST UPDATE : 2024-02-23
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Nearest centres:
POSTED : 2020-02-13 |
START DATE : 2020-02-10 |
LAST UPDATE : 2023-10-12
A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 2
Recruitment status: Recruiting
Study phase: Phase 2
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2020-10-12 |
LAST UPDATE : 2024-07-16
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2021-05-27 |
LAST UPDATE : 2024-07-18
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1
Recruitment status: Recruiting
Study phase: Phase 1
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2021-06-10 |
LAST UPDATE : 2024-07-16
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2021-07-07 |
LAST UPDATE : 2024-07-22
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2021-07-02 |
LAST UPDATE : 2024-07-24
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : 2021-08-25 |
START DATE : 2021-08-11 |
LAST UPDATE : 2024-06-05
MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : 2021-10-25 |
START DATE : 2021-10-08 |
LAST UPDATE : 2024-04-11
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 2
Recruitment status: Recruiting
Study phase: Phase 2
Recruitment status: Recruiting
Nearest centres:
POSTED : 2022-01-13 |
START DATE : 2021-12-07 |
LAST UPDATE : 2023-02-28
Early Integration of Palliative and Supportive Care in Cellular Therapy
Condition:
Multiple MyelomaHematologic Neoplasms
Study phase: N/A
Recruitment status: Recruiting
Study phase: N/A
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2022-02-16 |
LAST UPDATE : 2024-07-23
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2022-03-18 |
LAST UPDATE : 2024-07-15
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : 2022-05-12 |
START DATE : 2022-05-06 |
LAST UPDATE : 2024-02-26
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2022-08-25 |
LAST UPDATE : 2024-07-24
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2022-09-21 |
LAST UPDATE : 2024-07-15
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2022-09-21 |
LAST UPDATE : 2024-07-24
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2022-10-05 |
LAST UPDATE : 2024-07-15
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2022-10-26 |
LAST UPDATE : 2024-07-15
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : 2022-12-09 |
START DATE : 2022-11-30 |
LAST UPDATE : 2024-06-04
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
Condition:
Multiple Myeloma
Study phase:
Recruitment status: Recruiting
Study phase:
Recruitment status: Recruiting
Nearest centres:
POSTED : 2022-12-14 |
START DATE : 2022-12-06 |
LAST UPDATE : 2024-02-02
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1
Recruitment status: Recruiting
Study phase: Phase 1
Recruitment status: Recruiting
Nearest centres:
POSTED : 2022-12-15 |
START DATE : 2022-12-01 |
LAST UPDATE : 2023-10-23
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1
Recruitment status: Recruiting
Study phase: Phase 1
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2023-02-06 |
LAST UPDATE : 2024-07-22
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2023-09-13 |
LAST UPDATE : 2024-07-15
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2023-09-20 |
LAST UPDATE : 2024-07-04
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Nearest centres:
POSTED : 2023-09-28 |
START DATE : 2023-09-05 |
LAST UPDATE : 2024-06-17
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 4
Recruitment status: Recruiting
Study phase: Phase 4
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2023-10-11 |
LAST UPDATE : 2024-07-04
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Nearest centres:
POSTED : 2023-11-08 |
START DATE : 2023-11-02 |
LAST UPDATE : 2024-05-23
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1
Recruitment status: Recruiting
Study phase: Phase 1
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2023-11-17 |
LAST UPDATE : 2024-06-24
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2023-12-13 |
LAST UPDATE : 2024-07-17
Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2024-01-05 |
LAST UPDATE : 2024-07-16
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : |
START DATE : 2024-01-10 |
LAST UPDATE : 2024-06-27
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 1
Recruitment status: Recruiting
Study phase: Phase 1
Recruitment status: Recruiting
Nearest centres:
POSTED : 2024-01-25 |
START DATE : 2023-12-27 |
LAST UPDATE : 2024-02-07
Preliminary Assessment of [18F]BL40 in PET/CT Scans
Condition:
LymphomaMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseWaldenstrom Macroglobulinemia
Study phase:
Recruitment status: Not yet recruiting
Study phase:
Recruitment status: Not yet recruiting
Nearest centres:
POSTED : |
START DATE : 2024-02-19 |
LAST UPDATE : 2024-06-24
Prehab Prior to Stem Cell Transplantation in Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: N/A
Recruitment status: Not yet recruiting
Study phase: N/A
Recruitment status: Not yet recruiting
Nearest centres:
POSTED : |
START DATE : 2024-02-28 |
LAST UPDATE : 2024-07-10
Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 2
Recruitment status: Recruiting
Study phase: Phase 2
Recruitment status: Recruiting
Nearest centres:
POSTED : 2024-05-03 |
START DATE : 2024-05-01 |
LAST UPDATE : 2024-05-01
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 3
Recruitment status: Recruiting
Study phase: Phase 3
Recruitment status: Recruiting
Nearest centres:
POSTED : 2024-05-20 |
START DATE : 2024-03-11 |
LAST UPDATE : 2024-05-14
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Condition:
Multiple MyelomaNeoplasms, Plasma Cell
Study phase: Phase 2
Recruitment status: Not yet recruiting
Study phase: Phase 2
Recruitment status: Not yet recruiting
Nearest centres: